ELIMUSERTIB
Elimusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase ATR.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 1 | — | — | — | 6 |
| Recurrence | D012008 | — | — | 2 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | 1 | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | 1 | — | — | — | 1 |
| Alveolar rhabdomyosarcoma | D018232 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 5 | — | — | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | 3 | — | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | — | — | — | — | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 3 | — | — | — | — | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | — | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | — | — | — | — | 2 |
| Small cell carcinoma | D018288 | — | — | 2 | — | — | — | — | 2 |
| Small cell lung carcinoma | D055752 | — | — | 2 | — | — | — | — | 2 |
Show 32 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ELIMUSERTIB |
| INN | elimusertib |
| Description | Elimusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase ATR. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 1876467-74-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4647810 |
| ChEBI ID | — |
| PubChem CID | 118869362 |
| DrugBank | — |
| UNII ID | 7N13IK9LNH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ATR
ATR
Organism
Homo sapiens
Gene name
ATR
Gene synonyms
FRP1
NCBI Gene ID
Protein name
serine/threonine-protein kinase ATR
Protein synonyms
Ataxia telangiectasia and Rad3-related protein, FRAP-related protein 1, FRAP-related protein-1, MEC1, mitosis entry checkpoint 1, homolog
Uniprot ID
Mouse ortholog
Atr (245000)
serine/threonine-protein kinase ATR (Q9JKK8)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 280 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use